ALSO NOTED: FDA gives thumbs up to Hi-Tech Pharmacal drug;DC may license pharma reps;

> Hi-Tech Pharmacal got the FDA's OK to sell its version of Dermik Laboratories' Penlac nail fungus treatment. Release

> The District of Columbia's legislative body is considering a measure that would require all pharmaceuticals sales reps in the district to be licensed--and to get that license, they'd have to earn a bachelor's degree in pharmacy or science first. Report

> Aiming to boost its research into treatments for inflammatory diseases, German drug maker Evotec has agreed to buy U.S.-based Renovis for $151.8 million in stock. Report

> Merck has appointed ex-RJR Nabisco chief Steven Goldstone to its board. Release

> Meditrina Pharmaceuticals got the nod to manufacture the active ingredient in Pfizer CentreSource's drug candidate Femathina. Release

AND FINALLY... For two decades, biotech companies have struggled to develop therapeutic cancer vaccines. Now a crop of late-stage cancer vaccines are showing a lot of promise and attracting the attention of the large pharma and biotech companies. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.